Stay updated with breaking news from Pascal Deschatelets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) Director Alec Machiels sold 1,250 shares of the business’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $88.66, for a total transaction of $110,825.00. Following the transaction, the director now owns 267,641 shares of the company’s stock, valued at […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its target price hoisted by Oppenheimer from $96.00 to $108.00 in a research note issued to investors on Friday morning, The Fly reports. APLS has been the topic of a number of other reports. Robert W. Baird raised their price target on shares of Apellis Pharmaceuticals from $90.00 […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) shares gapped down before the market opened on Tuesday . The stock had previously closed at $88.11, but opened at $82.50. Apellis Pharmaceuticals shares last traded at $84.71, with a volume of 597,729 shares. Analyst Upgrades and Downgrades Several equities research analysts recently weighed in on APLS shares. […]
Skandinaviska Enskilda Banken AB publ decreased its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 16.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 30,846 shares of the company’s stock after selling 6,208 shares during the period. Skandinaviska Enskilda Banken […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) insider Pascal Deschatelets sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, May 8th. The shares were sold at an average price of $92.39, for a total value of $1,108,680.00. Following the completion of the transaction, the insider now directly owns 1,033,813 shares […]